Mounjaro activates two hormone pathways in your body simultaneously, making it the first drug in its class to do so. It mimics both GIP and GLP-1, two gut hormones that naturally spike after you eat. This dual action affects your pancreas, brain, liver, and fat tissue, producing changes in blood sugar, appetite, weight, and several cardiovascular markers. Here’s what happens at each level.
How It Works at the Receptor Level
Your gut normally releases GIP and GLP-1 after meals to help manage the incoming surge of nutrients. Mounjaro’s active ingredient, tirzepatide, is a single molecule engineered to hit both of these hormone receptors. It binds to the GIP receptor with roughly the same strength as the natural hormone, while its activity at the GLP-1 receptor is about fivefold weaker than natural GLP-1. Despite that imbalance, it still produces powerful effects through both pathways.
At the GIP receptor, tirzepatide drives insulin secretion and appears to improve how sensitive your cells are to insulin through a mechanism that’s independent of weight loss. At the GLP-1 receptor, it slows gastric emptying (how fast food leaves your stomach), suppresses appetite signals in the brain, and helps regulate blood sugar. The combination produces larger effects on weight and glucose than either pathway alone.
What Happens to Your Blood Sugar
When you eat, Mounjaro prompts your pancreas to release more insulin in response to rising glucose. This is “glucose-dependent,” meaning the drug only boosts insulin when blood sugar is actually elevated, which reduces the risk of dangerous blood sugar drops. Research using pancreatic islets from genetically modified mice confirmed that tirzepatide can enhance insulin secretion and reduce high blood sugar through either receptor independently, but the GIP receptor appears to be the primary driver of its insulin-boosting effect.
Interestingly, tirzepatide also stimulates glucagon, a hormone that raises blood sugar. This seems counterproductive, but glucagon plays other metabolic roles, including helping the liver process fat. The net effect on blood sugar is still strongly positive: in clinical trials, people with type 2 diabetes saw substantial reductions in HbA1c, the standard measure of long-term blood sugar control.
How Much Weight You Can Expect to Lose
In the landmark SURMOUNT-1 trial of adults with obesity (without diabetes), average weight loss at 72 weeks was 15% of body weight at the 5 mg dose, 19.5% at 10 mg, and 20.9% at the highest 15 mg dose. For someone starting at 230 pounds, that highest dose translates to roughly 48 pounds lost over about a year and a half.
Weight loss comes from two main drivers. First, Mounjaro suppresses appetite at the brain level, so you eat less without the same degree of hunger you’d feel on a calorie-restricted diet. Second, it slows gastric emptying, meaning food sits in your stomach longer and you feel full sooner during meals. The combined effect is a significant, sustained reduction in calorie intake.
The Muscle Loss Question
Not all of the weight you lose is fat. Case reports and reviews suggest that roughly a third of total weight lost on tirzepatide can come from skeletal muscle. In one documented case, a patient who lost about 15% of their body weight also lost 15% of their skeletal muscle mass, with muscle accounting for 34% of total weight lost. This ratio is similar to what’s seen with other forms of significant weight loss, including bariatric surgery, but it’s worth being aware of. Resistance training during treatment can help preserve muscle, which matters for long-term metabolism and physical function.
Changes in Your Liver and Abdominal Fat
One of Mounjaro’s most striking effects is on liver fat. Many people with type 2 diabetes or obesity carry excess fat in the liver, a condition that can quietly progress toward liver damage. In the SURPASS-3 MRI substudy, liver fat content dropped by roughly 30% at the 5 mg dose and by as much as 47% at the 10 mg dose after 52 weeks. These are substantial reductions that go beyond what weight loss alone would typically produce, suggesting the drug has direct metabolic effects on liver tissue. Abdominal fat and fat deposited within muscle also decreased.
Effects on Blood Pressure and Heart Rate
Mounjaro lowers blood pressure. In ambulatory monitoring studies, 24-hour systolic blood pressure dropped by 7.4 to 10.6 mmHg compared to placebo, depending on the dose. That’s a clinically meaningful reduction, roughly comparable to what a single blood pressure medication achieves.
The tradeoff is a modest increase in resting heart rate, ranging from about 2 to 5 beats per minute across dose levels. For most people this is not concerning, but it’s something your prescriber will monitor, especially if you have a pre-existing heart rhythm condition.
What It Does to Your Kidneys
In trials of people with obesity (with and without type 2 diabetes), tirzepatide reduced albumin in the urine, a marker of kidney stress, particularly in those who started with elevated levels. This improvement appeared by 24 weeks and held through 72 weeks. Importantly, the drug did not cause adverse changes in estimated kidney filtration rate (eGFR), and changes in kidney function did not correlate with the amount of weight lost. Kidney-related side effects occurred at similar rates in people taking tirzepatide and those on placebo (2 to 3%).
Gastrointestinal Side Effects
The most common side effects are digestive. Nausea affects roughly 30 to 40% of people, diarrhea 20 to 25%, vomiting 15 to 18%, and constipation 12 to 15%. These symptoms tend to be worst during the first few weeks on each new dose and typically ease as your body adjusts.
This is partly by design. Mounjaro starts at a low 2.5 mg dose that isn’t meant to control blood sugar or drive weight loss on its own. After four weeks, the dose increases to 5 mg, and from there it can be raised in 2.5 mg steps every four weeks or longer, up to a maximum of 15 mg weekly in adults. This gradual titration gives your gut time to adapt. Eating smaller meals, avoiding high-fat foods, and eating slowly can reduce nausea during dose increases.
Rare but Serious Risks
Mounjaro carries an FDA boxed warning about thyroid C-cell tumors. In rats, tirzepatide caused these tumors at doses comparable to what humans take, and the risk increased with higher doses and longer treatment. Whether this translates to humans is unknown, but the drug is contraindicated if you have a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2. A lump in the neck, difficulty swallowing, or persistent hoarseness are symptoms to take seriously.
Acute pancreatitis has also been reported. In clinical trials, it occurred in about 0.23 per 100 patient-years on tirzepatide versus 0.11 per 100 patient-years on comparators. Severe abdominal pain that radiates to the back, especially with nausea or vomiting, warrants immediate medical attention. Post-marketing reports have also included cases of intestinal obstruction and severe constipation leading to fecal impaction, though these remain uncommon.
How the Effects Build Over Time
Mounjaro’s effects are not instant. The first month at 2.5 mg is essentially a ramp-up period. Most people begin noticing appetite suppression within the first two to four weeks, but meaningful weight loss and blood sugar improvements typically become apparent after reaching the 5 mg dose or higher. Peak effects in clinical trials were measured at 72 weeks, suggesting the drug continues to work progressively over many months as doses are optimized and metabolic changes accumulate. Liver fat reduction, blood pressure improvements, and kidney benefits all followed a similar pattern of gradual, sustained change rather than a sudden shift.